News
News

The latest updates from AFAR.

Grantee in the News: Matt Kaeberlein affirms FDA caution on young blood transfusion in STAT News

Feb 22
2019

Grantee in the News: Matt Kaeberlein affirms FDA caution on young blood transfusion in STAT News View MoreBACK

 

On February 19, 2019, STAT News featured insights of AFAR expert Matt Kaeberlein, PhD in an article affirming the FDA’s recent warning against the rise of private companies promoting young blood transfusions to target age-related diseases.

Dr. Kaeberlein is a 2007 Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award recipient and Co-Director of the Nathan Shock Center of Excellence in the Biology of Aging at the University of Washington, for which AFAR serves as the Coordinating Center.

Read the article “FDA: Young-bloodtransfusions provide ‘no proven clinical benefit’ for aging, Alzheimer’s” here.


Read a related interview with AFAR expert Tom Rando, MD, PhD exploring what young blood reveals about the biology of aging and cautioning against the idea of young blood transfusions for humans, here.

 





View MoreBACK TO TOP